Peroxisome proliferator-activated receptor-γ regulates airway epithelial cell activation

American Journal of Respiratory Cell and Molecular Biology

Volumn 24, Issue 6, 2001, Pages 688-693

  Wang, A C C ^a   Dai, X ^a   Luu, B ^a   Conrad, D J ^a  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0034973231     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.24.6.4376     Document Type: Article

References (39)

1. Role of PPARs in health and disease
2. 12.14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
3. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
4. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR-γ)
5. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors
6. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
7. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer
8. Inflammation. Signalling the fat controller
9. The peroxisome proliferator-activated receptor (PPARgamma) as a regulator of monocyte/macrophage function
10. Expression and cDNA cloning of porcine peroxisome proliferator-activated receptor gamma (PPARγ)
11. Peroxisome proliferator-activated receptor gamma1 expression is induced during cyclic adenosine monophosphate-stimulated differentiation of alveolar type II pneumonocytes
12. Characterisation of bovine peroxisome proliferator-activated receptors γ1 and γ2: Genetic mapping and differential expression of the two isoforms
13. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase
14. Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells
15. Activators of the nuclear receptor PPARgamma enhance colon polyp formation
16. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
17. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
18. The nature and composition of 15-deoxy-Delta(12.14)PGJ(2)
19. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway
20. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappaB-binding sites
21. Enhanced AP-1 and NF-κB activities and stability of interleukin 8 (IL-8) transcripts are implicated in IL-8 mRNA superinduction in lung epithelial H292 cells
22. Nitric oxide in asthma: Pathogenic, therapeutic, or diagnostic?
23. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils
24. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer
25. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene
26. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
27. Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells
28. Regulation of 15-lipoxygenase expression in lung epithelial cells by interleukin-4
29. Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs
30. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis
31. Inhibition of inducible nitric oxide synthase expression by interleukin-4 and interleukin-13 in human lung epithelial cells
32. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation
33. Sudden-onset fatal asthma. A distinct clinical entity with few eosinophils and relatively more neutrophils in the airway submucosa?
34. The effect of diesel exhaust particles on cell function and release of inflammatory mediators from human bronchial epithelial cells in vitro
35. A comparison of cytokine release from epithelial cells cultured from nasal biopsy specimens of atopic patients with and without rhinitis and nonatopic subjects without rhinitis
36. Production of interleukin-8, RANTES and MCP-1 in intrinsic and extrinsic asthmatics
37. Airway remodeling in asthma
38. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits